• Explore /
  • Poster
  • / A phase Ib/II trial of lenvatinib (len) and letrozole (let) incorporating pharmacodynamics studies in postmenopausal women with hormone receptor positive (HR+) locally advanced/metastatic breast cancer (LABC/MBC).

A phase Ib/II trial of lenvatinib (len) and letrozole (let) incorporating pharmacodynamics studies in postmenopausal women with hormone receptor positive (HR+) locally advanced/metastatic breast cancer (LABC/MBC).

Abstract Poster

Authors

Joline Lim

Joline Si Jing Lim

National University Cancer Institute, Singapore, Singapore

Joline Si Jing Lim , Andrea Li Ann Wong , Samuel Guan Wei Ow , Lim Siew Eng , Raghav Sundar , Gloria HJ Chan , Kritika Yadav , Valerie Heong , David Shao Peng Tan , Ross A. Soo , Cheng Ean Chee , Wei-Peng Yong , Boon C. Goh , Soo-Chin Lee

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2019 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Breast Cancer—Metastatic

Track

Breast Cancer

Sub Track

Hormone Receptor-Positive

Clinical Trial Registration Number

NCT02562118

Citation

J Clin Oncol 37, 2019 (suppl; abstr 1045)

DOI

10.1200/JCO.2019.37.15_suppl.1045

Abstract #

1045

Poster Bd #

126

Abstract Disclosures

Similar Posters

First Author: Joline Si Jing Lim

First Author: Abhishek Tripathi

First Author: Markus H. Moehler

First Author: Panpan Zhang